01 — At a Glance
The Conglomerate Where Every Unit Is Playing a Different Game
- 52-Week High / Low₹3,325 / ₹2,314
- Q3 FY26 Revenue₹3,713 Cr
- Q3 FY26 PAT₹433 Cr
- Q3 FY26 EPS₹14.60
- Annualised EPS (9M avg×4)₹56.36
- Book Value₹447
- Price to Book5.86x
- Dividend Yield0.34%
- Debt / Equity0.35x
- TTM Revenue₹15,485 Cr
Auditor’s Opening Note: SRF closed Q3 FY26 with ₹3,713 crore revenue (+6% YoY), ₹433 crore PAT (+60% YoY), but buried inside these numbers are three wildly different businesses: specialty chemicals losing money to Chinese dumping, fluorochemicals on a record-breaking streak thanks to global quota restrictions, and packaging films showing early signs of Chinese competition discipline. The valuation reflects maximum confusion at 42x P/E — which is either a screaming bargain if Odisha’s next-gen refrigerants scale, or a rope if agro deferment persists and China decides to ignore Kigali quotas.
02 — Introduction
Welcome to SRF: The Company Even Management Doesn’t Fully Understand
Listen. SRF is not one company. It’s four companies pretending to be one. It makes refrigerant gases for air conditioners in an environment where global quotas are being enforced. It manufactures specialty chemicals for agrochemical majors who’ve decided to stop buying. It produces plastic films for FMCG packagers who are confused about GST rates. And it weaves industrial fabrics in a world where conveyor belts to the US are facing tariff uncertainties. All at the same time. All under one BSE ticker.
The stock is up 27% in 10 years but down 11% in one year. The P/E is 42x — which is 2.4x the industry median. Yet TTM profit is ₹1,849 crore, growing at 61% annually. The company is consciously sacrificing short-term pricing in specialty chemicals to hold market share against Chinese competitors it believes will eventually collapse under their own margin economics. Management is telling you that Chinese players “cannot sustain these prices… the question is not if, but when” correction happens. They’re betting. You’re paying 42x for the bet. This is either genius or insanity. The earnings call will help you decide which.
Incorporated in 1973, SRF has evolved from a niche technical textiles player to a conglomerate with presence in four business verticals, 16 manufacturing facilities, and export operations in 100+ countries. The company’s character is defined by one thing: long-term capital discipline masquerading as short-term chaos. They’re running a ₹12,300 crore capex cycle to future-proof the portfolio, but the near-term earnings visibility is worse than a monsoon forecast.
Concall Summary (Jan 2026): “PAT +60% YoY” sounds stellar until you learn it’s driven by 73 crore of wage-code exceptional items and 99 crore of favorable tax ITAT orders. Core operational leverage exists. But layering it under one-offs makes it hard to know if growth is real or optical.
03 — Business Model: Four Wars, One Scoreboard
If There’s a Price War, SRF Is Probably In It
SRF’s portfolio is split across four business verticals, each with wildly different margin profiles, growth trajectories, and competitive dynamics:
Chemicals Segment (41% of revenue, FY25)
Comprises specialty chemicals (agrochemical & pharma intermediates) and fluorochemicals (refrigerants, PTFEs, fluoropolymers). Highest margin (24.9% EBIT margin in FY25), most complex R&D. But specialty is in a pricing war against Chinese dumping. Management’s explicit strategy: “We have consciously chosen to protect our market share and volumes” over pricing.
Key driver now: Fluorochemicals record quarter on Kigali quota discipline. Agro deferment is real; pent-up Q4 POs expected. Pharma mix being pushed from ~10% to ≥20% of specialty.
Packaging Films (BOPP, BOPET, Foil) — 40% of revenue
Used in FMCG, food, electronics. Cyclical, commodity-like, but SRF is adding value-added product mix (BiLam, PCR films, capacitor-grade BOPP). Global presence (India, Thailand, Hungary, South Africa). Margin recovery underway post-China discipline. GST 2.0 caused domestic disruption; recovery from December expected.
Key driver now: Chinese authorities mandated 20% capacity cuts; further cuts post-Lunar holidays. SRF sees pricing uptick already. If sustained, significant margin tailwind.
Technical Textiles — 15% of revenue
Tyre cord (40% India market share), belting fabrics (2nd globally), industrial yarn. 40% market share in India’s nylon tyre cord. But facing aggressive Chinese pricing and lower US conveyor belt demand post-tariff uncertainty. Margins under pressure despite operational progress.
Key driver now: EcoVadis Silver Certification for sustainability, but price competition remains intense.
Others (Coated & Laminated Fabrics) — 3% of revenue
Flex hoardings, signage, architectural coatings. Soft domestic demand (Jal Jeevan mission liners), cheaper Chinese imports. Minimum import price withdrawal intensified competition. Off-season softness expected; focus on value-added tensile/semi-tensile products.
Key driver now: Margin protection via product mix shift upward.
The Hidden Leverage: 75-80% of SRF’s ₹22-23 crore planned FY26 capex is going into Chemicals. This segment has higher entry barriers, better margins, and Kigali quota tailwinds. If Odisha’s next-gen refrigerants (₹1,500-2,000 crore first stage) scale on time, ROCE expansion is locked in. But execution risk is real, and tariffs could derail R32 contracting.
💬 Here’s the bet: Chinese specialty chemical manufacturers cannot sustain pricing indefinitely. Do you agree with management’s 5-year conviction, or do you think dumping becomes the new normal?
04 — Financials Overview
Q3 FY26: The Numbers (With Caveats)
Result type: Quarterly Results | Q3 FY26 EPS: ₹14.60 | 9M Avg EPS (Jun, Sep, Dec) × 4: ₹56.36 | FY25 Full-Year EPS: ₹42.20
| Metric (₹ Cr) |
Q3 FY26
Dec 2025 |
Q3 FY25
Dec 2024 |
Q2 FY26
Sep 2025 |
YoY % |
QoQ % |
| Revenue | 3,713 | 3,491 | 3,640 | +6.4% | -2.0% |
| Operating Profit (EBIT) | 780 | 620 | 774 | +25.8% | +0.8% |
| OPM % | 21% | 18% | 21% | +300 bps | Stable |
| PAT | 433 | 271 | 388 | +59.8% | +11.6% |
| EPS (₹) | 14.60 | 9.14 | 13.10 | +59.7% | +11.5% |
The Caveat Sandwich: PAT +60% YoY sounds bulletproof until you extract the one-offs: ₹73 crore from wage code notification and ₹99 crore from favorable ITAT tax orders. Strip these out, and core PAT growth is closer to 25-30%. Still healthy, but not fireworks. Operational leverage is there — EBIT margin at 21% (vs 18% a year ago) — but the narrative is being padded by tax and exceptional items. The market is paying 42x P/E on operational improvements that are real but modest.
05 — Valuation: The ₹42,000 Crore Question
What’s the Market Paying For?
Join 10,000+ investors who read this every week.
